Patents Examined by Cheng Lu
  • Patent number: 12357690
    Abstract: In the present disclosure, the effect of the TGF?/Smad3/EPB41L5 molecular mechanism on cancer cells has been identified, and it has been found that high expression of EPB41L5 is correlated with poor overall survival of cancer patients, indicating that EPB41L5 is a potential prognostic marker of cancer. Thus, the present disclosure specifies an epitope of EPB41L5 to allow EPB41L5 to be recognized as an antigen, and relates to an antibody or a fragment thereof which binds specifically to the epitope. The antibody according to the present disclosure may be usefully employed as a therapeutic agent for EPB41L5-related cancer.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: July 15, 2025
    Assignee: Cellaster, Inc.
    Inventors: Kyung Chul Choi, Ho Geun Yoon, Jae Ho Cheong, Mi Hyeon Jeong
  • Patent number: 12344646
    Abstract: Provided is an antibody-tumor necrosis factor ? fusion protein and its preparation and applications. Specifically, the present disclosure relates to a fusion protein comprising an antibody moiety and a TNF? moiety, a nucleic acid molecule encoding same, a nucleic acid construct, a host cell and a method of production thereof, as well as applications of these materials in prevention and/or treatment of tumors.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: July 1, 2025
    Inventor: Bang Ding
  • Patent number: 12338284
    Abstract: Provided is an anti-PD-L1 monoclonal antibody. The antibody can be used to prepare a drug for preventing or treating a disease related to PD-L1.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: June 24, 2025
    Assignee: HUABO BIOPHARM (SHANGHAI) CO., LTD.
    Inventors: Haijia Yu, Ling Yu, Mingqing Cai, Xiangyang Zhu
  • Patent number: 12325747
    Abstract: The present disclosure is directed to antibodies binding to PD-L1 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1.
    Type: Grant
    Filed: November 17, 2022
    Date of Patent: June 10, 2025
    Assignee: Board of Regents, The University of Texas System
    Inventors: Michael A. Curran, Carlo Toniatti, Ashvin R. Jaiswal, Dongxing Zha, Kui Voo, Bianka Prinz, Nadthakarn Boland
  • Patent number: 12319749
    Abstract: Disclosed are an antibody or a functional fragment thereof binding to 3?-sialyl lactose and comprising a heavy chain variable region which is optionally substituted with 3 or less amino acids and which comprises a CDR sequence consisting of an amino acid sequence ARKNGGLDYAMDY (SEQ ID NO: 3), a polynucleotide encoding the antibody or the functional fragment thereof, an expression vector comprising the polynucleotide, and a test drug for a disease and a pharmaceutical composition comprising the antibody or the functional fragment thereof.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: June 3, 2025
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Kiyoshi Higashi, Koichi Saito
  • Patent number: 12310999
    Abstract: Biomarkers useful for identifying a variety of cancers that are responsive to treatment with a combination therapy comprising pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof and talimogene laherparepvec are provided. Methods of treating cancers that are resistant to monotherapy with pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof are provided. Methods of treating a cancer in a subject having a tumor with a low CD8+ density, a low or negative interferon gamma signature, and/or a low or negative PD-L1 status are also provided.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: May 27, 2025
    Assignees: MERCK SHARP & DOHME CORP., AMGEN INC.
    Inventors: Jennifer Lorraine Gansert, Abraham Antonio Anderson, Kevin Gorski
  • Patent number: 12312413
    Abstract: Described and provided herein are novel antibodies for Claudin 18.2. Also described and provided are pharmaceutical compositions of the antibodies and methods of use for the treatment of cancer.
    Type: Grant
    Filed: November 21, 2022
    Date of Patent: May 27, 2025
    Assignees: Jiangsu AoSaiKang Ph
    Inventors: Yuefeng Lu, Kurt Shanebeck, Lu Li, Lei Liu, Shiwen Zhang, Lan Yang, Jian-Feng Lu
  • Patent number: 12296012
    Abstract: Provided herein are antibodies that specifically bind to Fms-like tyrosine kinase 3 (FLT3), chimeric antigen receptors (CARs) that specifically bind to FLT3, and engineered immune cells expressing such CARs (e.g. FLT3-specific CAR-T cells). The invention also provides making such antibodies, CARs, and engineered immune cells. The invention also provides using such antibodies, CARs, and engineered immune cells, for example for the treatment of a condition associated with malignant cells expressing FLT3 (e.g., cancer).
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: May 13, 2025
    Assignee: PFIZER INC.
    Inventors: Barbra Johnson Sasu, Danielle Elizabeth Dettling, Cesar Adolfo Sommer, Yik Andy Yeung, Moustafa Marc Hamze
  • Patent number: 12281171
    Abstract: The present inventors have developed antigen-binding reagents and antigen-binding conjugates that recognize a cancer-specific glycan (carbohydrate) modification on the human Periostin protein. Various in vitro and in vivo diagnostic and/or therapeutic methods using these compositions are also disclosed herein specifically for treating cancers that have amplification of the Mgat3 gene.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: April 22, 2025
    Assignees: Bio Ventures, LLC, SRI International
    Inventors: Karen Abbott, Nathalie Scholler
  • Patent number: 12269896
    Abstract: The present invention provides novel antibodies that specifically bind to GUCY2c and uses thereof in the treatment of cancer. The present invention further provides novel bispecific antibodies comprising such antibodies and uses thereof in the treatment of cancer.
    Type: Grant
    Filed: October 27, 2022
    Date of Patent: April 8, 2025
    Assignee: PFIZER INC.
    Inventors: Chew Shun Chang, Gurkan Guntas, Madan Katragadda, Divya Mathur, Adam Reid Root, Lidia Mosyak, Edward Roland Lavallie
  • Patent number: 12252746
    Abstract: Disclosed herein are methods of treating a subject having a cancer characterized by a modification at biomarker 1q21, which comprises administering to the subject a therapeutically effective amount of an anti-CD46 antibody.
    Type: Grant
    Filed: July 27, 2022
    Date of Patent: March 18, 2025
    Assignee: The Regents of the University of California
    Inventors: Bin Liu, Daniel W. Sherbenou, Blake T. Aftab, Yang Su, Christopher R. Behrens
  • Patent number: 12252702
    Abstract: Disclosed herein are methods and compositions related to the treatment, prevention, and/or amelioration of cancer in a subject in need thereof.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: March 18, 2025
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Liang Deng, Jedd Wolchok, Stewart Shuman, Taha Merghoub, Ning Yang, Yi Wang, Gregory Mazo, Peihong Dai, Weiyi Wang
  • Patent number: 12215078
    Abstract: The invention relates to chemically reactive and/or biologically active compounds, reagents and compositions thereof. More particularly, the invention provides novel reagents that are useful in chemical synthesis, functionalization, delivery, probing and/or analytical measurements of small molecule drugs, proteins, antibodies and other biomolecules. The invention provides novel biologically active agents useful as diagnostics or therapeutics, and related composition and methods of uses thereof.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: February 4, 2025
    Assignee: University of Massachusetts
    Inventors: Sankaran Thayumanavan, Richard W. Vachet, Jiaming Zhuang, Bo Zhao
  • Patent number: 12209134
    Abstract: Provided is an anti-human Fn14 antibody which binds to human Fn14 to inhibit an action via the human Fn14, thereby preventing or treating cancer cachexia. The inventors have conducted studies on an anti-human Fn14 antibody, and provided an anti-human Fn14 antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 2 and a light chain consisting of the amino acid sequence of SEQ ID NO: 4.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: January 28, 2025
    Assignee: Astellas Pharma Inc.
    Inventors: Misato Ito, Risa Kashiwagi, Masakatsu Kawakami
  • Patent number: 12195551
    Abstract: The invention relates to methods of treating of subject that has breast cancer or is at risk of having said cancer, comprising administering to the subject in need thereof a combination of a therapeutically effective amount of an ErbB-2/ErbB-3 bispecific antibody and a therapeutically effective amount of an endocrine therapy drug, wherein the bispecific antibody has an antigen binding site that can bind an extra-cellular part of ErbB-2 and an antigen binding site that can bind an extra-cellular part of ErbB-3; and to means for said method.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: January 14, 2025
    Assignee: Merus N.V.
    Inventors: David Andre Baptiste Maussang-Detaille, Cecilia Anna Wilhelmina Geuijen
  • Patent number: 12195725
    Abstract: The subject matter disclosed herein is generally directed to tissue specific modulation of Th17 differentiation and pathogenicity by targeting tissue specific Th17 gene programs and gene targets. The tissue specific modulation may be used therapeutically to treat a disease or condition in the tissue where it arises. The subject matter disclosed herein is also directed to detecting tissue specific Th17 cells for diagnostic and therapeutic methods.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: January 14, 2025
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc., The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventors: Meromit Singer, Alexandra Schnell, Aviv Regev, Vijay K. Kuchroo
  • Patent number: 12178887
    Abstract: Disclosed is a tumor-specific antibody and fluorophore conjugate for detecting, localizing and imaging of various tumors. Also disclosed are methods for detecting, localizing and imaging a solid tumor before or during a tumor resection surgery using the antibody-fluorophore conjugate.
    Type: Grant
    Filed: January 26, 2023
    Date of Patent: December 31, 2024
    Assignees: CITY OF HOPE, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Paul Yazaki, Jack Shively, Michael Bouvet, Jonathan Delong, Yuman Fong
  • Patent number: 12171763
    Abstract: Provided herein are combination therapies (compositions) and methods and uses thereof for the treatment lung cancer, where the combination therapies comprise Compound 1 or a pharmaceutically acceptable salt thereof as described herein and a PD-L1 binding antagonist (e.g., atezolizumab).
    Type: Grant
    Filed: November 11, 2021
    Date of Patent: December 24, 2024
    Assignee: Genentech, Inc.
    Inventors: Marie Evangelista, Mark Andrew Merchant, Jennifer Lee Schutzman, Ting-Kun Mark Lin, Stephanie Royer Joo, Sandhya Vinayak Mandlekar
  • Patent number: 12171829
    Abstract: Methods of treatment of colorectal cancer can include the administration of the anti-alpha-v integrin (receptor) antibody Abituzumab. Preferably, the methods of treating colorectal cancer can include treating Stage II-IV colorectal cancer, metastatic colorectal cancer, left-sided colorectal cancer and/or left-sided metastatic colorectal cancer, involving the administration of said Abituzumab to patients in need thereof. Abituzumab is also useful for the manufacture of a medicament for treating colorectal cancer, preferably colorectal cancer as defined herein. Abituzumab is further useful for the manufacture of a medicament for treating colorectal cancer in combination with suitable targeted therapy concepts, such as growth factor or growth factor receptor targeting monoclonal antibodies, and/or chemotherapy.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: December 24, 2024
    Assignee: Merck Patent GmbH
    Inventors: Giorgio Massimini, Ilhan Celik, Josef Straub, Rolf Bruns, Rita Laeufle
  • Patent number: 12161642
    Abstract: The invention relates to a method of treatment of a patient with a ferrochelatase inhibitor, or a pharmaceutically acceptable salt thereof, or a derivative thereof. Also, the invention relates to a method of treatment of a patient with a ferrochelatase inhibitor that is a triazolopyrimidinone, or a derivative thereof, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: December 10, 2024
    Assignees: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION, Gachon University of Industry—Academic Cooperation
    Inventors: Timothy W. Corson, Kamakshi Sishtla, Seung-Yong Seo, Bit Lee